Put companies on watchlist
Viromed Medical AG
ISIN: DE000A3MQR65
WKN: A3MQR6
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Viromed Medical AG · ISIN: DE000A3MQR65 · EQS - Company News (8 News)
Country: Germany · Primary market: Germany · EQS NID: 1886067
22 April 2024 04:30PM

Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care® by Viromed with significant growth potential


EQS-News: Viromed Medical AG / Key word(s): Alliance
Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care® by Viromed with significant growth potential

22.04.2024 / 16:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care® by Viromed with significant growth potential

Pinneberg, 22 April 2024 –
Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusive use of the pioneering cold plasma therapy with Plasma Care® by Viromed for their 1,250,000 patients and is establishing Plasma Care® by Viromed as the benchmark in Germany. According to market studies, in Germany alone this important cooperation gives around 40 percent of patients with acute and chronic wounds access to the market-leading cold plasma therapy in terms of the number of devices supplied. By using Plasma Care® by Viromed as an exclusive treatment method in one of the largest networks for dermatology and phlebology practices in Europe, Viromed Medical AG expects significant growth potential and anticipates an additional earnings contribution of EUR 0.28 to EUR 0.34 per share from the 2025 financial year onwards.

CORIUS Group, according to its own information the largest dermatology and phlebology practice network in Germany, Switzerland, and the Netherlands, will exclusively use cold plasma therapy with Plasma Care® by Viromed in its 77 locations with its own practices and clinics in Germany. Viromed Medical AG believes that the use of Plasma Care® by Viromed by the CORIUS Group will have a signal effect for wound treatment in Germany, further accelerating the spread of innovative cold plasma therapy.

Uwe Perbandt, CEO of Viromed Medical AG: ”This agreement is a real milestone for the economic success of our company. It also underlines the CORIUS Group's confidence in our Plasma Care® by Viromed technology and its importance for the future of wound treatment. Through the exclusive use of our pioneering cold plasma therapy in the facilities of the CORIUS Group with its 1,250,000 patients, Plasma Care® by Viromed will play a key role in innovative wound care. We are convinced that other clinics and care facilities will follow the CORIUS Group's example.“

About Viromed Medical AG:

Viromed Medical AG has a broad customer base in the DACH region, including various DAX companies, e.g. Volkswagen and Lufthansa, as well as federal states and various federal ministries, 1,100 hospitals, 7,000 pharmacies, and 17,000 medical practices.

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
Germany
Email: kontakt@viromed-medical.de
www.viromed-medical-ag.de



22.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Viromed Medical AG
Flensburger Straße 18
25421 Pinneberg
Germany
Phone: +49 4101 809960
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A3MQR65
WKN: A3MQR6
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg
EQS News ID: 1886067

 
End of News EQS News Service

1886067  22.04.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1886067&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Viromed Medical AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.